Rafael Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. on November 5, 2018. The report details a specific corporate event involving the partial exercise of a warrant by IDT-Rafael Holdings, LLC, a 90%-owned subsidiary of the Registrant.
Key Financial Metrics and Transaction Details
- Transaction Amount: $5.0 million total purchase price for 4.0 million shares of Rafael Pharmaceuticals, Inc. Series D Convertible Preferred Stock.
- Funding Source: $4.5 million contributed by the Subsidiary and $500,000 contributed by a minority interest holder in the Subsidiary.
- Ownership Stake: Following the exercise, the Registrant and its subsidiaries collectively own 19.0% of Rafael Pharmaceuticals' outstanding capital stock and 11.6% on a fully diluted basis (excluding the remainder of the Warrant).
- Warrant Capacity: The Warrant is exercisable for up to 56.0% of the equity of Rafael Pharmaceuticals.
Material Changes and Ownership Structure
The filing reports a material change in the Registrant's equity interest in Rafael Pharmaceuticals, Inc. The effective interest breakdown is as follows:
| Category | Outstanding Basis | Fully Diluted* |
|---|---|---|
| Rafael Holdings | 11.4% | 6.9% |
| Other holders of equity in subsidiaries | 7.6% | 4.7% |
| Total | 19.0% | 11.6% |
*Excluding the exercise of the remainder of the Warrant.
Use of Proceeds and Management Commentary
The proceeds from the partial warrant exercise will be utilized by Rafael Pharmaceuticals to fund expenses related to Phase III clinical trials of its flagship compound, CPI-613, as well as other trial phases, research, and general corporate purposes. The filing does not provide specific revenue, profit, cash flow, or debt metrics for Rafael Holdings, Inc. itself, as this is an event-driven report rather than a periodic financial statement.
Investor Verification Checklist
- Verify the current status and progress of the Phase III clinical trials for CPI-613.
- Confirm the remaining exercisable amount of the Warrant and potential future dilution.
- Review the financial health and capitalization of Rafael Pharmaceuticals, Inc. to assess the value of the 19.0% stake.
- Check for any subsequent filings regarding the full exercise of the Warrant or changes in the minority interest holder's contribution.